Skip to main content
KANGSTEM BIOTECH CO., LTD. logo

KANGSTEM BIOTECH CO., LTD. — Investor Relations & Filings

Ticker · 217730 ISIN · KR7217730001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2024-11-28 M&A Activity
Country KR South Korea
Listing KO 217730

About KANGSTEM BIOTECH CO., LTD.

https://kangstem.com

KANGSTEM BIOTECH CO., LTD. is a biopharmaceutical company that researches and develops advanced stem cell therapies. The company focuses on creating treatments for rare, incurable, and autoimmune diseases, with a pipeline that includes therapeutic candidates for neurological disorders. Leveraging proprietary technologies for the isolation and mass culture of mesenchymal stem cells, Kangstem Biotech also develops and commercializes stem cell culture media and related cosmetic products. The company is dedicated to addressing unmet medical needs through the development of next-generation biopharmaceuticals.

Recent filings

Filing Released Lang Actions
[첨부추가]주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a merger decision (회사합병 결정) between Kangstem Biotech and Primoris Therapeutics. It details the merger method, purpose, impact, ratios, and schedule. In the context of Korean regulatory filings (DART), this is a formal announcement of a merger transaction, which falls under the M&A Activity category.
2024-11-28 Korean
투자판단관련주요경영사항(임상시험계획변경승인신청) (퓨어스템에이디주(FURESTEMAD Inj.)의 반복투여 1/2a 임상시험계획 변경승인신청)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from a Korean biotech company (Kangstem Biotech) regarding an application for a change in clinical trial plans (IND amendment) submitted to the Ministry of Food and Drug Safety (MFDS). It details the clinical trial design, objectives, and rationale for the change. Since it is a specific regulatory announcement regarding clinical trial status and does not fit into financial reporting or corporate governance categories, it is classified as a Regulatory Filing (RNS).
2024-11-18 Korean
투자판단관련주요경영사항(임상시험결과) (퓨어스템에이디주(FURESTEMAD Inj.) 제3상 임상시험 결과보고서(CSR) 수령)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory disclosure filed by Kangstem Biotech regarding the receipt of a Phase 3 Clinical Study Report (CSR) for their drug candidate, FURESTEM-AD. It details the clinical trial methodology, primary endpoints, statistical results (which failed to meet superiority), and safety data. This is a standard 'Major Management Matter' disclosure (투자판단 관련 주요경영사항) common in the Korean stock market (KRX) for reporting clinical trial outcomes, which falls under the category of Regulatory Filings (RNS) as it is a formal announcement of material information.
2024-11-18 Korean
투자판단관련주요경영사항 (제대혈 유래 줄기세포 아토피피부염 치료제 국내 독점판권/통상실시권 설정 및 기술전수 계약 해제)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system (KIND) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It specifically announces the termination of a licensing and technology transfer agreement for a stem cell treatment. Since this is a specific regulatory disclosure of a material event that does not fit into categories like M&A, dividends, or financial reports, it falls under the general regulatory filing category.
2024-11-18 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Kangstem Biotech, covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial data, business operations, capital structure, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-13 Korean
투자판단관련주요경영사항 (무릎골관절염치료제(OSCA) 국내 라이선스 계약 체결)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Kangstem Biotech) announcing a licensing agreement for a knee osteoarthritis treatment (OSCA). It details the contract terms, financial milestones, and counterparty information. Since this is a specific corporate announcement regarding a business transaction (licensing/partnership) that does not fit into the other specialized categories like M&A or share issues, it is classified as a general regulatory filing.
2024-11-07 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.